Literature DB >> 3181141

Mutational analysis of the 5' non-coding region of human immunodeficiency virus type 1: effects of secondary structure on translation.

N T Parkin1, E A Cohen, A Darveau, C Rosen, W Haseltine, N Sonenberg.   

Abstract

The first 111 nt from the 5' end of human immunodeficiency virus type 1 (HIV-1) mRNAs are shown to have a strong inhibitory effect on the translation of mRNA in in vitro translation extracts as well as in Xenopus oocytes. Mutations in the sequence of the 5' untranslated region (UTR) designed to disrupt predicted secondary structure of this region relieve the inhibition. Inhibition is restored by mutations that reconstruct the predicted secondary structure. The accessibility of the 5'-terminal cap structure was also found to be increased by some of these mutations. We conclude that secondary structure in the 5' UTR of HIV-1 mRNAs and resultant inaccessibility of the cap structure is responsible for the inhibition of translation. The implications of these findings for the understanding of the life cycle of HIV-1 are discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3181141      PMCID: PMC457075          DOI: 10.1002/j.1460-2075.1988.tb03139.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  37 in total

1.  Cap accessibility correlates with the initiation efficiency of alfalfa mosaic virus RNAs.

Authors:  T Godefroy-Colburn; M Ravelonandro; L Pinck
Journal:  Eur J Biochem       Date:  1985-03-15

2.  Insertion mutagenesis to increase secondary structure within the 5' noncoding region of a eukaryotic mRNA reduces translational efficiency.

Authors:  J Pelletier; N Sonenberg
Journal:  Cell       Date:  1985-03       Impact factor: 41.582

3.  The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat.

Authors:  C A Rosen; J G Sodroski; W A Haseltine
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

4.  Location of the trans-activating region on the genome of human T-cell lymphotropic virus type III.

Authors:  J Sodroski; R Patarca; C Rosen; F Wong-Staal; W Haseltine
Journal:  Science       Date:  1985-07-05       Impact factor: 47.728

5.  Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus.

Authors:  C A Rosen; E Terwilliger; A Dayton; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

6.  Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter.

Authors:  D A Melton; P A Krieg; M R Rebagliati; T Maniatis; K Zinn; M R Green
Journal:  Nucleic Acids Res       Date:  1984-09-25       Impact factor: 16.971

7.  Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat.

Authors:  J Sodroski; C Rosen; F Wong-Staal; S Z Salahuddin; M Popovic; S Arya; R C Gallo; W A Haseltine
Journal:  Science       Date:  1985-01-11       Impact factor: 47.728

8.  The epidemiology of AIDS: current status and future prospects.

Authors:  J W Curran; W M Morgan; A M Hardy; H W Jaffe; W W Darrow; W R Dowdle
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

9.  Trans-activator gene of human T-lymphotropic virus type III (HTLV-III).

Authors:  S K Arya; C Guo; S F Josephs; F Wong-Staal
Journal:  Science       Date:  1985-07-05       Impact factor: 47.728

10.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  83 in total

Review 1.  Destiny of unspliced retroviral RNA: ribosome and/or virion?

Authors:  Melinda Butsch; Kathleen Boris-Lawrie
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  The major mRNA-associated protein YB-1 is a potent 5' cap-dependent mRNA stabilizer.

Authors:  V Evdokimova; P Ruzanov; H Imataka; B Raught; Y Svitkin; L P Ovchinnikov; N Sonenberg
Journal:  EMBO J       Date:  2001-10-01       Impact factor: 11.598

3.  HIV-1 protease cleaves eukaryotic initiation factor 4G and inhibits cap-dependent translation.

Authors:  I Ventoso; R Blanco; C Perales; L Carrasco
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

4.  The requirement for eukaryotic initiation factor 4A (elF4A) in translation is in direct proportion to the degree of mRNA 5' secondary structure.

Authors:  Y V Svitkin; A Pause; A Haghighat; S Pyronnet; G Witherell; G J Belsham; N Sonenberg
Journal:  RNA       Date:  2001-03       Impact factor: 4.942

5.  Substrate affinity and substrate specificity of proteasomes with RNase activity.

Authors:  Karine Gautier-Bert; Bertrand Murol; Anne-Sophie Jarrousse; Lionel Ballut; Saloua Badaoui; Frank Petit; Hans-Peter Schmid
Journal:  Mol Biol Rep       Date:  2003-03       Impact factor: 2.316

6.  Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro.

Authors:  C A Bohan; F Kashanchi; B Ensoli; L Buonaguro; K A Boris-Lawrie; J N Brady
Journal:  Gene Expr       Date:  1992

7.  Variable inhibition of cell-free translation by HIV-1 transcript leader sequences.

Authors:  A P Geballe; M K Gray
Journal:  Nucleic Acids Res       Date:  1992-08-25       Impact factor: 16.971

8.  Regulation of the Epstein-Barr virus DNA polymerase gene.

Authors:  F B Furnari; M D Adams; J S Pagano
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

9.  Eukaryotic protein synthesis: still a mystery.

Authors:  William C Merrick
Journal:  J Biol Chem       Date:  2010-05-05       Impact factor: 5.157

10.  RU5 of Mason-Pfizer monkey virus 5' long terminal repeat enhances cytoplasmic expression of human immunodeficiency virus type 1 gag-pol and nonviral reporter RNA.

Authors:  Stacey Hull; Kathleen Boris-Lawrie
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.